3Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer:a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys, 1994,28:847-856.
4Leveque FG, Montgomery M, Potter DA, et al. Multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patient. J Clin Oncol, 1993, 11: 1124- 1131.
5Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Eng J Med, 1993,329:390-395.
6Nishimura Y, Nakamatsu K, Kanamori S, et al. Importance of mean dose and initial volume ofparotid glands in xerostomia of patients with head and neck cancer receiving IMRT. Int J Radiat Oncol Biol Phys ,2004 ,60:522.
7Kauko S,Manri K,Juhani C,et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol,2005 ,74 :251-258.
8Clifford C, Navneet M, Chih-jen H, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma:a comparison with conventional techniques. Radiother Oncol,2001,61:275- 280.
9Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys,2002,53:12-22.
10Avraham E, Hyungjin MK, Jeffrey ET, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys,2001,50 :695-704.
